A RANDOMIZED, OBSERVER-BLIND, MULTICENTER, PHASE 2B STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A PLANT-DERIVED QUADRIVALENT VLP INFLUENZA VACCINE IN ADULTS 18-64 YEARS OF AGE
- Registry ID
- CP-Q14VLP-009
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MEDICAGO INC
- Start date
- 2016-09-16
- Last update
- 2015-08-12
Conditions
Related clinical trials
- A RANDOMIZED, OBSERVER-BLIND, ADAPTIVE, ACTIVE COMPARATOR-CONTROLLED, DOSE-RANGING, MULTICENTER, SAFETY, TOLERABILITY, AND IMMUNOGENICITY PHASE 1/2 STUDY OF A PLANT-BASED SEASONAL RECOMBINANT TRIVALENT VLP INFLUENZA VACCINE IN ADULTS 18 YEARS OF AGE
- A CONTROLLED HUMAN INFECTION MODEL FOR INFLUENZA: A PHASE 1 TRIAL TARGETING A/H3N2 STRAIN AS A FOUNDATION FOR PANDEMIC PREPAREDNESS
- PANDEMIC INFLUENZA VACCINE IN ORGAN TRANSPLANTATION (PIVOT TRIAL: SAFETY AND IMMUNOGENICITY OF PANDEMIC INFLUENZA VACCINE IN KDNEY TRANSPLANT RECIPIENTS
- ADAPTIVE PLATFORM TRIAL OF TREATMENTS FOR RESPIRATORY INFECTIONS IN COMMUNITY SETTINGS (TREATRESP)
- A PHASE 3, RANDOMIZED, OBSERVER-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1010 CANDIDATE SEASONAL INFLUENZA VACCINE IN ADULTS 50 YEARS AND OLDER
- A PHASE 1, RANDOMIZED, RATER AND SUBJECT BLINDED PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, TOLERABILITY AND IMMUNOGENICITY OF A STANDARD AND A FRACTIONAL DOSE OF H1 INFLUENZA VACCINE DELIVERED BY VX-103 (A MIMIX MICRONEEDLE PATCH (MAP) SYSTEM) IN HEALTHY ADULTS ¿18-39 YEARS OF AGE.
View on source registry